Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Inventory (2016 - 2019)

Historic Inventory for Ironwood Pharmaceuticals (IRWD) over the last 8 years, with Q4 2019 value amounting to $648000.0.

  • Ironwood Pharmaceuticals' Inventory changed N/A to $648000.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $648000.0, marking a year-over-year change of. This contributed to the annual value of $648000.0 for FY2019, which is N/A changed from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Inventory of $648000.0 as of Q4 2019.
  • In the past 5 years, Ironwood Pharmaceuticals' Inventory registered a high of $5.0 million during Q1 2015, and its lowest value of $76000.0 during Q3 2018.
  • In the last 5 years, Ironwood Pharmaceuticals' Inventory had a median value of $1.1 million in 2016 and averaged $1.4 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Inventory tumbled by 8413.36% in 2018, and later surged by 292368.42% in 2019.
  • Over the past 5 years, Ironwood Pharmaceuticals' Inventory (Quarter) stood at $5.0 million in 2015, then tumbled by 78.16% to $1.1 million in 2016, then plummeted by 32.01% to $735000.0 in 2017, then plummeted by 89.66% to $76000.0 in 2018, then soared by 752.63% to $648000.0 in 2019.
  • Its last three reported values are $648000.0 in Q4 2019, $2.3 million for Q3 2019, and $1.7 million during Q2 2019.